This systematic literature review reports incidence of adverse drug effects associated with guideline-directed medical therapy for patients with heart failure with reduced ejection fraction.
Ralph J. Riello III, PharmD
Advertisement
Articles by Ralph J. Riello III, PharmD
Best Practices for Implementing Venous Thromboembolism Prophylaxis Across the Continuum of Care
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
The Use of Betrixaban for Extended Prophylaxis of Venous Thromboembolism Events in Hospitalized, High-Risk Patients
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
Advertisement
Latest Updated Articles
- Adverse Drug Effects Across Patients With Heart Failure: A Systematic Review
Published: March 14th 2022 | Updated:
- Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis
Published: November 17th 2018 | Updated:
- The Use of Betrixaban for Extended Prophylaxis of Venous Thromboembolism Events in Hospitalized, High-Risk Patients
Published: November 17th 2018 | Updated:
- Best Practices for Implementing Venous Thromboembolism Prophylaxis Across the Continuum of Care
Published: November 17th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Value-Based Care Interventions and Management of CKD Progression
5
